{"nctId":"NCT00144339","briefTitle":"Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients","startDateStruct":{"date":"2002-12"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":5993,"armGroups":[],"interventions":[{"name":"tiotropium","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent.\n* Male or female patients 40 years of age or older.\n* Smoking history of at least 10 pack years.\n* Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1\\<70% of FVC and on stable respiratory medication.\n\nExclusion Criteria:\n\n* Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate.\n* Myocardial infarction in past 6 months.\n* Unstable or life threatening arrhythmia in past year.\n* Hospitalization for NYHA heart failure class III or IV in past year.\n* Active tuberculosis.\n* Asthma.\n* Pulmonary resection.\n* Malignancy treated with radiation or chemotherapy in past 5 years.\n* Respiratory infection in 4 weeks prior to screening.\n* Known hypersensitivity to anticholinergic drugs or components.\n* Known moderate to severe renal impairment.\n* Known narrow angle glaucoma.\n* Significant symptomatic BPH or bladder neck obstruction.\n* Need for oxygen therapy \\>12 hr/day.\n* Use of oral corticosteroids at unstable doses or \\>10 mg/day.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years","description":"Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30","spread":"1"},{"groupId":"OG001","value":"-30","spread":"1"}]}]}]},{"type":"PRIMARY","title":"Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years","description":"Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42","spread":"1"},{"groupId":"OG001","value":"-40","spread":"1"}]}]}]},{"type":"SECONDARY","title":"Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment","description":"Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17","spread":"2"},{"groupId":"OG001","value":"-15","spread":"2"}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment","description":"Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32","spread":"2"},{"groupId":"OG001","value":"-27","spread":"2"}]}]}]},{"type":"SECONDARY","title":"Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years","description":"Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39","spread":"3"},{"groupId":"OG001","value":"-43","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years","description":"Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61","spread":"3"},{"groupId":"OG001","value":"-61","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years","description":"Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41","spread":"3"},{"groupId":"OG001","value":"-47","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years","description":"Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-65","spread":"3"},{"groupId":"OG001","value":"-66","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score","description":"SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":"0.09"},{"groupId":"OG001","value":"1.25","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment","description":"Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12","spread":"4"},{"groupId":"OG001","value":"-10","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment","description":"Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40","spread":"4"},{"groupId":"OG001","value":"-40","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment","description":"Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17","spread":"4"},{"groupId":"OG001","value":"-17","spread":"4"}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment","description":"Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46","spread":"4"},{"groupId":"OG001","value":"-42","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Time to First Exacerbation","description":"Chronic obstructive pulmonary disease (COPD) exacerbation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.51","spread":null},{"groupId":"OG001","value":"16.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"0.02"},{"groupId":"OG001","value":"0.73","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2049","spread":null},{"groupId":"OG001","value":"2001","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Exacerbation Days Per Patient Year","description":"Number of exacerbation days normalized by treatment exposure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.64","spread":"0.35"},{"groupId":"OG001","value":"12.11","spread":"0.32"}]}]}]},{"type":"SECONDARY","title":"Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.64","spread":null},{"groupId":"OG001","value":"35.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"811","spread":null},{"groupId":"OG001","value":"759","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"25.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Exacerbation Leading to Hospitalization","description":"Estimated number of exacerbations leading to hospitalizations per patient year","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization","description":"Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"0.17"},{"groupId":"OG001","value":"3.17","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1","description":"Estimated FEV1 before bronchodilator at Month 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.134","spread":"0.004"},{"groupId":"OG001","value":"1.221","spread":"0.004"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1","description":"Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.372","spread":"0.004"},{"groupId":"OG001","value":"1.418","spread":"0.004"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6","description":"Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.126","spread":"0.004"},{"groupId":"OG001","value":"1.225","spread":"0.004"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.365","spread":"0.004"},{"groupId":"OG001","value":"1.423","spread":"0.004"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.111","spread":"0.004"},{"groupId":"OG001","value":"1.213","spread":"0.004"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.345","spread":"0.004"},{"groupId":"OG001","value":"1.398","spread":"0.004"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.101","spread":"0.005"},{"groupId":"OG001","value":"1.192","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.326","spread":"0.005"},{"groupId":"OG001","value":"1.379","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.079","spread":"0.005"},{"groupId":"OG001","value":"1.173","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.294","spread":"0.005"},{"groupId":"OG001","value":"1.356","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.061","spread":"0.005"},{"groupId":"OG001","value":"1.156","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.274","spread":"0.005"},{"groupId":"OG001","value":"1.335","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.045","spread":"0.005"},{"groupId":"OG001","value":"1.144","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.250","spread":"0.005"},{"groupId":"OG001","value":"1.315","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.034","spread":"0.005"},{"groupId":"OG001","value":"1.129","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42","description":"Estimated FEV1 after bronchodilator at Month 42","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.236","spread":"0.006"},{"groupId":"OG001","value":"1.297","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.024","spread":"0.006"},{"groupId":"OG001","value":"1.112","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.219","spread":"0.006"},{"groupId":"OG001","value":"1.268","spread":"0.006"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.667","spread":"0.008"},{"groupId":"OG001","value":"2.856","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.149","spread":"0.007"},{"groupId":"OG001","value":"3.204","spread":"0.006"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.658","spread":"0.009"},{"groupId":"OG001","value":"2.862","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.137","spread":"0.008"},{"groupId":"OG001","value":"3.193","spread":"0.007"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.640","spread":"0.009"},{"groupId":"OG001","value":"2.838","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.110","spread":"0.008"},{"groupId":"OG001","value":"3.158","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.622","spread":"0.010"},{"groupId":"OG001","value":"2.816","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.075","spread":"0.009"},{"groupId":"OG001","value":"3.126","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.597","spread":"0.010"},{"groupId":"OG001","value":"2.785","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.036","spread":"0.009"},{"groupId":"OG001","value":"3.095","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.572","spread":"0.010"},{"groupId":"OG001","value":"2.757","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.010","spread":"0.010"},{"groupId":"OG001","value":"3.057","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.553","spread":"0.011"},{"groupId":"OG001","value":"2.753","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.973","spread":"0.010"},{"groupId":"OG001","value":"3.038","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.540","spread":"0.011"},{"groupId":"OG001","value":"2.724","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.959","spread":"0.011"},{"groupId":"OG001","value":"3.005","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.532","spread":"0.011"},{"groupId":"OG001","value":"2.702","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.929","spread":"0.011"},{"groupId":"OG001","value":"2.961","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.847","spread":"0.008"},{"groupId":"OG001","value":"3.017","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.280","spread":"0.007"},{"groupId":"OG001","value":"3.318","spread":"0.007"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.841","spread":"0.009"},{"groupId":"OG001","value":"3.027","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.268","spread":"0.008"},{"groupId":"OG001","value":"3.304","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.820","spread":"0.009"},{"groupId":"OG001","value":"2.996","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.228","spread":"0.008"},{"groupId":"OG001","value":"3.260","spread":"0.008"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.811","spread":"0.010"},{"groupId":"OG001","value":"2.965","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.195","spread":"0.009"},{"groupId":"OG001","value":"3.234","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.775","spread":"0.010"},{"groupId":"OG001","value":"2.942","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.157","spread":"0.009"},{"groupId":"OG001","value":"3.189","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.738","spread":"0.011"},{"groupId":"OG001","value":"2.908","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.126","spread":"0.010"},{"groupId":"OG001","value":"3.157","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.731","spread":"0.011"},{"groupId":"OG001","value":"2.897","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.086","spread":"0.010"},{"groupId":"OG001","value":"3.136","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.713","spread":"0.011"},{"groupId":"OG001","value":"2.875","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.073","spread":"0.011"},{"groupId":"OG001","value":"3.100","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.696","spread":"0.012"},{"groupId":"OG001","value":"2.846","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.041","spread":"0.011"},{"groupId":"OG001","value":"3.067","spread":"0.011"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.289","spread":"0.240"},{"groupId":"OG001","value":"39.409","spread":"0.233"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.501","spread":"0.253"},{"groupId":"OG001","value":"39.730","spread":"0.245"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.067","spread":"0.278"},{"groupId":"OG001","value":"40.474","spread":"0.269"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.562","spread":"0.297"},{"groupId":"OG001","value":"41.178","spread":"0.286"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.342","spread":"0.315"},{"groupId":"OG001","value":"41.919","spread":"0.301"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.280","spread":"0.326"},{"groupId":"OG001","value":"41.935","spread":"0.311"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.722","spread":"0.342"},{"groupId":"OG001","value":"42.905","spread":"0.325"}]}]}]},{"type":"SECONDARY","title":"Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48","description":"* SGRQ total score summarizes the impact of COPD on overall patient's health status.\n* Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.\n* The scale is continuous.\n* Rate of decline shows the yearly change of SGRQ total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.968","spread":"0.357"},{"groupId":"OG001","value":"43.665","spread":"0.338"}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)","description":"On-treatment defined as day 1 to completion of double blinded treatment plus 30 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"402","spread":null},{"groupId":"OG001","value":"374","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"12.5","spread":null}]}]}]},{"type":"POST_HOC","title":"Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1440 Days)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"491","spread":null},{"groupId":"OG001","value":"430","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)","description":"All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"495","spread":null},{"groupId":"OG001","value":"446","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)","description":"The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)","description":"The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (System Organ Class = Cardiac Disorders)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null},{"groupId":"OG001","value":"322","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.21","spread":null},{"groupId":"OG001","value":"3.56","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Angina)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":null},{"groupId":"OG001","value":"0.51","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Atrial Fibrillation)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":null},{"groupId":"OG001","value":"0.74","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":null},{"groupId":"OG001","value":"0.61","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure Congestive)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Coronary Artery Disease)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"0.21","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Myocardial Infarction)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.69","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (System Organ Class = Lower Respiratory System Disorders)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"985","spread":null},{"groupId":"OG001","value":"911","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.47","spread":null},{"groupId":"OG001","value":"11.32","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Bronchitis)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":null},{"groupId":"OG001","value":"0.37","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Chronic Obstructive Pulmonary Disease (COPD) Exacerbation)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"742","spread":null},{"groupId":"OG001","value":"688","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.70","spread":null},{"groupId":"OG001","value":"8.19","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Dyspnoea)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":null},{"groupId":"OG001","value":"0.38","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Pneumonia)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null},{"groupId":"OG001","value":"296","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":null},{"groupId":"OG001","value":"3.28","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Incidence Rate of Serious Adverse Event (Preferred Term = Respiratory Failure)","description":"Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":null},{"groupId":"OG001","value":"0.90","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1509},"commonTop":["COPD exacerbation","Dyspnoea","Nasopharyngitis","Upper respiratory tract infection","Hypertension"]}}}